Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MAGE-C1 CRISPR/Cas9 KO Plasmid (h): sc-403336
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MAGE-C1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MAGE-C1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MAGE-C1 Antibody (CT7-33): sc-53868
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-C1 CRISPR/Cas9 KO Plasmid (h) | sc-403336 | 20 µg | $397.00 |
Overview
MAGEC1 encodes MAGE-C1, a cancer-testis antigen of the MAGE family with restricted expression in normal adult tissues and frequent upregulation in malignant cells. MAGE-C1 is implicated in regulation of protein homeostasis through interactions with E3 ubiquitin ligase complexes, influencing ubiquitination-dependent proteasomal turnover and stress-response signaling. Aberrant expression has been associated with tumor cell survival programs, altered apoptosis, and modulation of immune recognition pathways. As a lineage- and tumor-associated marker, MAGE-C1 is commonly studied in the context of oncogenic signaling, antigen presentation biology, and mechanisms underlying cellular adaptation to proteotoxic stress.
MAGE-C1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MAGEC1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MAGEC1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MAGEC1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MAGE-C1 protein expression.
This CRISPR knockout system enables efficient generation of MAGEC1-deficient cell models for investigation of MAGE-C1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MAGEC1 exon(s) critical for MAGE-C1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MAGEC1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MAGE-C1 CRISPR/Cas9 KO Plasmid (h) and MAGE-C1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MAGEC1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MAGE-C1 HDR Plasmid (h) and MAGE-C1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MAGEC1 homology arms to support homology-directed repair at defined MAGEC1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.